Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

BridgeBio Pharma  (Stock symbol: BBIO )

421 Kipling Street
Palo Alto, CA 94301
USA
650-391-9740
Website Company Summary Management Team
Management

CEO: Neil Kumar (9/30/2014)
General Management: Hector Rodriguez
Finance: Brian C. Stephenson (10/31/2018)
Technology: Uma Sinha (4/30/2016)
Business Development: Cameron Turtle
General Counsel/Legal: Barbara Bispham
Former Employees: Ralph Scarborough
Board

Outside board: (May no longer be on the board) James C. Momtazee (Kohlberg Kravis Roberts & Co.) Ali J. Satvat (KKR) Eric Aguiar (Aisling Capital Partner)
Company

Business description: BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio is committed to developing leaders as well as drugs.
Partners include: Infinity PharmaceuticalsLexicon PharmaceuticalsSt. Jude Medical;  MD Anderson Cancer Center;  Shire;  University of California, San Francisco
Capital

Rounds: 2
Recent Fundings: Jun 2020   Sep 2017
Capital raised: 434.0M
Last Round: 299.0M
Ownership: Public   Ipo Filing
Stock Symbol: BBIO
VCs include: Sequoia CapitalHercules CapitalAisling Capital Viking Global Investors ;  Cormorant Capital;  Janus Fund
Corporate investors: AIG Investments
Private equity: KKR

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2021
Sector: Medical Devices & Diagnostics
Year Founded: 2015
Headcount: 201-300 as of May 2019
Rounds: 2
Recent Fundings: Jun 2020   Sep 2017
Capital Raised: 434.0M
Last Round: 299.0M
Ownership: Public   Ipo Filing
Stock Symbol: BBIO